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years ago, first clinical trials on safety and immunogenicity. In
the meantime more than 25,000 women have been included into
several efficacy trials which demonstrated protection against
persistent infection with HPV 16 and 18 and against the develop-
ment of precursor lesions to cervical cancer. Although the ulti-
mate proof of success, i.e. reduction of cancer incidence still
requires the immunization of large populations and many years
of follow-up, the existing data are so persuasive that the first
marketing of the vaccine is expected to be announced in mid
2006. Yet several questions such as the duration of protection,
the need development of for post-exposure vaccination strate-
gies and availability of such vaccine in low-budget countries
are open and will be discussed.
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S39. IDENTIFICATION OF POTENTIAL TARGET ANTIGENS FOR
IMMUNOTHERAPY APPROACHES
Dirk Ja¨ger. Medizinische Onkologie, Nationales Centrum fu¨r
Tumorerkrankungen, Universita¨tsklinik Heidelberg, Germany.
Immunotherapy approaches in cancer rely on the identification of
suitable antigens that can be used as targets for therapeutic
approaches. The ideal target antigen is highly and homogenously
expressed in cancer, but not or low level expressed in normal tis-
sues. Using different cloning techniques, several potential target
antigens have been identified, some of these antigens are already
being evaluated in clinical trials. We followed a cloning strategy
called SEREX that identifies tumor antigens based on a spontane-
ous humoral immune response in patients. Using this technique
we identified 2 new tumor associated antigens that belong to the
group of differentiation antigens: NY-BR-1 as a new breast differ-
entiation antigen and RAB38/NY-MEL-1 as a new melanocyte dif-
ferentiation antigen.
NY-BR-1 is not expressed in normal tissues except in nor-
mal mammary gland and testis, but it is highly expressed in
70% of breast cancers. Antigen positive cancers maintain the
expression in metastatic lesions. Spontaneous antibody
responses occur in about 10% of breast cancer patients. We
identified 2 HLA-A2 restricted NY-BR-1 derived epitopes that
were recognized by CD8+ T cells from patients with NY-BR-1
expressing cancers. Both epitopes are naturally processed and
presented.
RAB38/NY-MEL-1 is expressed in melanocytes and at low level
in adrenal gland, all other normal tissues are RAB38/NY-MEL-1
mRNA negative. Spontaneous humoral immune responses are
frequent in melanoma patients but not in normal individuals,
in patients with vitiligo or with cancers other than melanoma.
We recently identified a HLA-A2 restricted RAB38/NY-MEL-1
derived epitope that is naturally processed and presented and
recognized by CD8 T cells.
Both new antigens, NY-BR-1 and RAB38/NY-MEL-1 are being
evaluated as targets for T cell based immunotherapy strategies
in Phase-I trials.
doi:10.1016/j.ejcsup.2006.04.040
S40. T CELL BASED IMMUNOTHERAPY – CHANGES AND
CHALLENGES
Volker Schirrmacher. Division of Cellular Immunology, German
Cancer Research Center, Heidelberg, Germany.
Advances in cellular and molecular immunology have led to the
development of strategies for effective augmentation of anti-
tumor immune-responses in cancer patients. This presentation
focuses on the manipulation of T cell immunity either by
active-specific immunization with tumor vaccines1–4 or by adop-
tive immunotherapy with immune T cells.5,6 Such therapies offer
exquisite specificity of tumor recognition based on the ability of
the T cell to distinguish single amino acid differences in any pro-
tein from any compartment of the tumor cell.
Recent analyses of bone marrow samples from patients with
a variety of different cancers revealed the existence of cancer
reactive memory T cells in a high proportion and at high fre-
quencies.5–9 A fine specificity analysis revealed individuality (i)
of response patterns to multiple tumor associated antigens
(TAAs), (ii) of the size and (iii) of the specificity of the memory
repertoire in the bone marrow of cancer patients. These findings
challenge immunotherapy approaches targeting single TAAs.
Future strategies will be discussed for the exploitation of the
TAA memory repertoire of cancer patients. In ‘‘proof of princi-
ple’’ studies it was demonstrated to have great therapeutic
potential.5,6
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S41. TARGETING THE APOPTOTIC PATHWAY TO INDUCE
RADIORESISTANCE IN NORMAL TISSUE AND STEM CELLS
Frederik Wenz. Department of Radiation Oncology, Mannheim
Medical Center, University of Heidelberg, Germany.
Novel strategies in clinical radiotherapy have the goal to
increase the therapeutic index i.e. effective tumor cell kill while
sparing the normal tissue. This can be achieved by either phys-
ical selectivity when the tumor is well circumscribed or by bio-
logical selectivity when normal tissue is present in the
treatment volume. Biological selectivity can be achieved by tar-
geting tissue properties which are only present either in tumor
or normal tissue cells.
Radiation induced apoptosis is a rare event as compared to
mitogenic death in epithelial tumor cells. In contrast, radiation
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induced apoptosis for example of endothelial cells or bone mar-
row stem cells is clinically relevant as initiating step for normal
tissue damage after radiotherapy.
We have established several gene-therapeutic approaches to
suppress radiation induced apoptosis by overexpression of
super-oxide dismutase (SOD) and P-glycoprotein (P-gp) the prod-
uct of the multi-drug resistance gene (MDR). Clonogenic assays
showed that radioresistance can be induced in normal tissue
cells (e.g. human primary lung fibroblasts), whereas the survival
of human tumor cells (e.g. HeLa) after radiotherapy is not
altered. Using differential gene expression analysis and quanti-
tative real-time PCR, we showed up-regulation of detoxification
genes and down-regulation of pro-apoptotic genes (e.g. CASP1,
CASP4).
Targeting the apoptotic pathway to induce radioresistance in
normal tissue cells is a potential strategy to increase the thera-
peutic index in radiation oncology.
doi:10.1016/j.ejcsup.2006.04.042
S42. CHALLENGES IN DEFINING GENETIC RISKS FOR FAMILIAL
COLORECTAL CANCER
Peter Propping. Institute of Human Genetics, University of Bonn,
Bonn, Germany.
Twenty to twenty-five percent of all cases of colorectal cancer
(CRC) show some familiarity. Although the role of genes is not
yet completely understood, a number of well-defined genetic dis-
ease entities is known to contribute to the familiarity: Lynch syn-
drome (formerly hereditary nonpolyposis colorectal cancer,
HNPCC), familial adenomatous polyposis (FAP), MYH-associated
polyposis (MAP), juvenile polyposis, Peutz–Jeghers syndrome.
The most common genetic form of CRC is Lynch syndrome that
is responsible for 2–3% of all cases. The analysis of these diseases
led to valuable insights into the disease process also of the spo-
radic forms of CRC.
We need a filter system within the public health care system
that allows the detection of families with an increased genetic
risk. Individuals belonging to such families should first undergo
genetic counselling. Genetic analysis can largely differentiate
between the risks. Persons at increased risk should be included
in a risk-adapted screening programme. Only specialized centers
for inherited CRC will be able to efficiently organize programs of
CRC prevention.
The ongoing collaborative study of the German Cancer Aid will
give clear data as to the efficacy of systematic cancer prevention
in Lynch syndrome through early detection, particularly through
colonoscopy and gynecological examinations.
doi:10.1016/j.ejcsup.2006.04.043
S43. MOLECULAR DIAGNOSIS OF HEREDITARY COLORECTAL
CANCERS
Hans K. Schackert. Department of Surgical Research, Technische
Universita¨t Dresden, Germany.
Hereditary colorectal cancer accounts for up to 5% of all colo-
rectal cancers. A variety of known and unknown genes are
responsible for the two known phenotypes. Familial adenoma-
tous polyposis coli (FAP) is phenotypically characterized by
hundreds or even thousands of polyps in the colon and rectum
and by a very high incidence of colorectal cancer at young age.
FAP is caused by the tumour suppressor gene APC and is a
highly penetrant autosomal condition, while the phenotypically
similar MUTYH-associated polyposis is an autosomal recessive
disease.
The much more frequent hereditary non-polyposis colorectal
cancer syndrome (HNPCC) is caused by mutations in five mis-
match repair (MMR) genes. Although no clear-cut genotype/phe-
notype correlations in pathogenic mutations carriers of the
same MMR gene have been identified, distinct phenotypic differ-
ences are associated with mutations in different MMR genes. The
mode of inheritance of HNPCC is autosomal dominant, yet a
small but increasing number of very young patients have been
reported as carriers of biallelic MMR gene mutations. Notably,
their phenotype is different from the HNPCC phenotype and
resembles the phenotype of MMR gene knockout mice. In addi-
tion to an incomplete penetrance of about 80% for colorectal can-
cers, and susceptibility to a wide range of tumours, the age of
onset of HNPCC varies widely, ranging from 16 to 90 years. We
have identified additional genetic factors located in p53 and RNA-
SEL that influence age of disease onset in HNPCC patients carry-
ing a pathogenic MMR germline mutation.
In conclusion, mutations in a variety of genes can cause
hereditary colorectal cancer. In addition to genetic heterogeneity,
there is evidence for multiple genetic factors that contribute to
the development of disease. Identification of causative genetic
and environmental factors may contribute to a more detailed
tumour risk assessment in carriers of mutations in MMR genes.
Particularly, the knowledge of the age of onset of disease in carri-
ers of pathogenic germline mutations in MMR genes might affect
preventive strategies, including age at first surveillance, surveil-
lance intervals, and age at preventive surgery.
doi:10.1016/j.ejcsup.2006.04.044
S44. EGFR-SIGNALLING IN COLON CANCER
R. Kopp. Department of Surgery, Klinikum Grosshadern, LMU Munich,
Germany.
Activation of the epidermal growth factor receptor (EGFR) path-
way seems to be involved in the regulation of proliferation and
invasion in gastrointestinal tumors. In colon cancer increased
EGFR levels were reported in advanced and more invasive carci-
nomas. Recently EGFR-inhibitors are used as a new treatment
option in patients not responding to standard chemotherapy.
However, EGFR-signalling is dependent on the presence of var-
ious EGFR ligands and mechanisms of ligand presentation. In
addition several other mechanisms involved in the regulation
of EGFR binding have been reported (PKC, Syk, Mig6, SIRPs).
Furthermore costimulatory effects between other G-protein
coupled receptor (GPCR) were shown to increase tumor cell
proliferation.
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